Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Indication and the general instruction to avoid live vaccines during Cosentyx therapy are supported, but multiple vaccine claims are over-specific or overly absolute (e.g., naming MMR/varicella/oral poliovirus as contraindicated; stating inactivated/subunit vaccines are categorically safe and that flu vaccine can be given). Several statements about immune suppression and increased likelihood/severity of reactions to live vaccines are not supported by the provided label text.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and active ankylosing spondylitis.
1.1, 1.2, 1.3
Avoid use of live vaccines in patients treated with Cosentyx.
5.7
Unsupported Statements
Cosentyx suppresses the immune system.
The provided label text does not explicitly support the standalone general statement that Cosentyx 'suppresses the immune system' (the label provided mainly discusses immune response effects in the context of live vaccines).
Patients receiving Cosentyx may be more likely to experience adverse reactions to live vaccines, including severe reactions.
Not supported by the provided prescribing information excerpts.
Inactivated vaccines are safe to receive during Cosentyx treatment.
The provided label excerpt (5.7) does not state that inactivated vaccines are categorically 'safe' during treatment.
Subunit vaccines are safe to receive during Cosentyx treatment.
The provided label excerpt (5.7) does not state that subunit vaccines are categorically 'safe' during treatment.
Patients can receive the flu vaccine during Cosentyx treatment.
The provided label excerpt (5.7) does not explicitly endorse flu vaccination during treatment.
The flu vaccine is an inactivated vaccine.
The provided label excerpt does not establish the composition/type of 'the' flu vaccine.
Inactivated vaccines contain killed or inactivated pathogens.
Not supported by the provided prescribing information excerpts.
Subunit vaccines contain only a portion of the pathogen.
Not supported by the provided prescribing information excerpts.
Contradictions
Low
AI Statement
The MMR vaccine is contraindicated in patients receiving biologic medications like Cosentyx.
Label Reference
4, 5.7
Low
AI Statement
The chickenpox vaccine is contraindicated in patients receiving biologic medications like Cosentyx.
Label Reference
4, 5.7
Low
AI Statement
The oral poliovirus vaccine is contraindicated in patients receiving biologic medications like Cosentyx.
Label Reference
4, 5.7
Important Omissions
The label’s instruction is to avoid live vaccines (without listing specific vaccines). The AI claims provide named vaccine contraindications rather than aligning with the label’s class-based guidance.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Over-specific contraindication statements for named vaccines and over-absolute claims about safety/eligibility of certain vaccines (inactivated/subunit/flu) are not supported by the provided label excerpt. These mismatches could lead to incorrect vaccination decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple vaccine-related assertions are more specific or more categorical than the provided label text (5.7), including named contraindications (MMR/varicella/oral poliovirus) and blanket safety/administration permissions for inactivated/subunit/flu vaccines.
Suggested Improvement
Limit vaccine statements to the label-supported guidance in 5.7: consider completing age-appropriate immunizations before starting Cosentyx and avoid use of live vaccines during treatment; avoid naming specific vaccines as contraindicated and avoid categorical claims that inactivated/subunit vaccines are 'safe' or that patients 'can' receive flu vaccination.